<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To examine the chemopreventive effect of selective cyclooxygenase-2 (COX-2) inhibitor <z:chebi fb="0" ids="41423">celecoxib</z:chebi> for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Fifty 8-week-old male Sprague Dawley rats underwent esophagojejunostomy to induce <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain>Four weeks after operation the animals were given <z:chebi fb="0" ids="41423">celecoxib</z:chebi> 10 mg/(kg*d(-1))(<z:chebi fb="0" ids="41423">celecoxib</z:chebi> group), or saline 1 ml (control group) </plain></SENT>
<SENT sid="3" pm="."><plain>Another 10 rats were sham operation group </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> animals were sacrificed at 20 week after surgery </plain></SENT>
<SENT sid="5" pm="."><plain>The degree of <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, COX-2 expression and <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) of animals were assessed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULT: Among 60 rats, 6 rats died in <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group, 8 rats died in control group, 1 rat died in sham operation group, and 45 (75%) rats completed the study </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of mild, moderate and severe degree <z:mp ids='MP_0003278'>esophageal inflammation</z:mp> in <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group and control group was 14/19(73.68%), 4/19(21.05%), 1/19(5.26%); 4/17(23.53%), 5/17(29.41%), 8/17(47.06%)(P&lt;0.05), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> was 7/19(36.84%), 13/17(76.47%) in two group respectively(P&lt;0.05); The incidence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> was 2/19(10.53%), 8/17(47.06%)(P&lt;0.05), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The expression of COX-2 was 1/7(14.29%), 10/13(76.92%)(P&lt;0.05) in two groups </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="15551">PGE2</z:chebi> content was significantly lower in the <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group than that in control group(P&lt;0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>No esophageal pathological changes were found in sham operation group </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Selective COX-2 inhibitors <z:chebi fb="0" ids="41423">celecoxib</z:chebi> can inhibit <z:mp ids='MP_0001845'>inflammations</z:mp>, development of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and esophagus <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>